To identify modulators of sensitivity or resistance to DDX3X inhibition by RK-33, a genome-wide CRISPR/Cas9 chemogenomic screen was conducted in NALM-6 cells, a human pre-B acute lymphoblastic leukemia cell line for which the screening protocol had been previously established (Bertomeu et al., 2018). This evidence concerns the gene DDX3X and acute lymphoblastic leukemia.